Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab for PRCA after ABO-mismatched HSCT
NCT05559827Phase 2Not yet recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Sep 2022
- Primary completion
- Oct 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 2, randomised, open-label trial of isatuximab in pure red cell aplasia (PRCA), sponsored by Assistance publique - Hôpitaux de Paris. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
isatuximab
03
Conditions
pure red cell aplasia (PRCA)
Beyond the preview
Go deeper on NCT05559827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05559827.